Korean J Health Promot.  2021 Jun;21(2):56-62. 10.15384/kjhp.2021.21.2.56.

Validation of Fatty Liver Index as a Marker for Non-Alcoholic Fatty Liver Disease

• Park SW
• Han AL

• KMID: 2517398
• DOI: http://doi.org/10.15384/kjhp.2021.21.2.56

Abstract

Background
Many studies have been conducted to validate fatty liver index (FLI) as a marker for non-alcoholic fatty liver disease (NAFLD). However, there are insufficient data in Korea to verify the usefulness of FLI, and the results of these studies are contradictory. This study aimed to validate FLI as a marker for NAFLD in Korea. For better accuracy, computed tomography (CT) scan was used instead of ultrasound scan.
Methods
A cross-sectional analysis was performed in 785 subjects who participated in a health examination. The participants were divided according to presence of NAFLD, which was determined by abdominal CT. Frequency analysis was performed on all results. The chi-square test and independent t-test were used to compare the differences between the non-NAFLD group and the NAFLD group in terms of general characteristics and blood tests. The ability of the FLI to detect (nonalcoholic) fatty liver was assessed using area under the receiver operator characteristic (AUROC) curve analysis.
Results
FLI was significantly higher in the NAFLD group (42.48±27.63) than in the non-NAFLD group (22.59±20.05) (P<0.0001). The algorithm for FLI had a better AUROC of 0.696 (95% confidence interval, 0.649-0.742) than any other variable in the prediction of NAFLD.
Conclusions
FLI is a marker that can be used as a simple and cost-effective tool to screen for NAFLD.

Keyword

Non-alcoholic fatty liver disease; Obesity; Index

Figure

• 

  Figure 1. Receiver operator characteristic curves for fatty liver index (FLI). FLI performed better than any single variable (all P values <0.0001).

Reference

1. Non-alcoholic Fatty Liver Disease Study Group, Lonardo A, Bellentani S, Argo CK, Ballestri S, Byrne CD, et al. Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups. Dig Liver Dis. 2015; 47(12):997–1006.

2. Lee YH, Cho Y, Lee BW, Park CY, Lee DH, Cha BS, et al. Nonalcoholic fatty liver disease in diabetes. Part I: epidemiology and diagnosis. Diabetes Metab J. 2019; 43(1):31–45.

3. Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011; 9(6):524–30.e1. quiz e60.

4. Hyysalo J, Männistö VT, Zhou Y, Arola J, Kärjä V, Leivonen M, et al. A population-based study on the prevalence of NASH using scores validated against liver histology. J Hepatol. 2014; 60(4):839–46.

5. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol. 2012; 107(6):811–26.

6. Poynard T, Ratziu V, Naveau S, Thabut D, Charlotte F, Messous D, et al. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol. 2005; 4:10.

7. Kotronen A, Peltonen M, Hakkarainen A, Sevastianova K, Bergholm R, Johansson LM, et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology. 2009; 137(3):865–72.

8. Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, et al. Hepatic steatosis index: a simple screening tool reflecting non-alcoholic fatty liver disease. Dig Liver Dis. 2010; 42(7):503–8.

9. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006; 6:33.

10. Koehler EM, Schouten JN, Hansen BE, Hofman A, Stricker BH, Janssen HL. External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study. Clin Gastroenterol Hepatol. 2013; 11(9):1201–4.

11. Meffert PJ, Baumeister SE, Lerch MM, Mayerle J, Kratzer W, Völzke H. Development, external validation, and comparative assessment of a new diagnostic score for hepatic steatosis. Am J Gastroenterol. 2014; 109(9):1404–14.

12. Carvalhana S, Leitão J, Alves AC, Bourbon M, Cortez-Pinto H. How good is controlled attenuation parameter and fatty liver index for assessing liver steatosis in general population: correlation with ultrasound. Liver Int. 2014; 34(6):e111–7.

13. Yang BL, Wu WC, Fang KC, Wang YC, Huo TI, Huang YH, et al. External validation of fatty liver index for identifying ultrasonographic fatty liver in a large-scale cross-sectional study in Taiwan. PLoS One. 2015; 10(3):e0120443.

14. Huang X, Xu M, Chen Y, Peng K, Huang Y, Wang P, et al. Validation of the fatty liver index for nonalcoholic fatty liver disease in middle-aged and elderly Chinese. Medicine (Baltimore). 2015; 94(40):e1682.

15. Jiang ZY, Xu CY, Chang XX, Li WW, Sun LY, Yang XB, et al. Fatty liver index correlates with non-alcoholic fatty liver disease, but not with newly diagnosed coronary artery atherosclerotic disease in Chinese patients. BMC Gastroenterol. 2013; 13:110.

16. Kim JH, Kwon SY, Lee SW, Lee CH. Validation of fatty liver index and lipid accumulation product for predicting fatty liver in Korean population. Liver Int. 2011; 31:1600–1.

17. Hashimoto E, Taniai M, Tokushige K. Characteristics and diagnosis of NAFLD/NASH. J Gastroenterol Hepatol. 2013; 28 Suppl 4:64–70.

18. Pickhardt PJ, Park SH, Hahn L, Lee SG, Bae KT, Yu ES. Specificity of unenhanced CT for non-invasive diagnosis of hepatic steatosis: implications for the investigation of the natural history of incidental steatosis. Eur Radiol. 2012; 22(5):1075–82.

19. Li Q, Dhyani M, Grajo JR, Sirlin C, Samir AE. Current status of imaging in nonalcoholic fatty liver disease. World J Hepatol. 2018; 10(8):530–42.

20. Lawrence DA, Oliva IB, Israel GM. Detection of hepatic steatosis on contrast-enhanced CT images: diagnostic accuracy of identification of areas of presumed focal fatty sparing. AJR Am J Roentgenol. 2012; 199(1):44–7.

21. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988; 44(3):837–45.

22. Koehler EM, Schouten JN, Hansen BE, van Rooij FJ, Hofman A, Stricker BH, et al. Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam study. J Hepatol. 2012; 57(6):1305–11.

23. Wong RJ, Ahmed A. Obesity and non-alcoholic fatty liver disease: disparate associations among Asian populations. World J Hepatol. 2014; 6(5):263–73.

24. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004; 40(6):1387–95.

25. Guerrero R, Vega GL, Grundy SM, Browning JD. Ethnic differences in hepatic steatosis: an insulin resistance paradox? Hepatology. 2009; 49(3):791–801.

26. Barchetta I, Angelico F, Del Ben M, Baroni MG, Pozzilli P, Morini S, et al. Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. BMC Med. 2011; 9:85.

27. Seo JA, Eun CR, Cho H, Lee SK, Yoo HJ, Kim SG, et al. Low vitamin D status is associated with nonalcoholic fatty liver disease independent of visceral obesity in Korean adults. PLoS One. 2013; 8(10):e75197.

28. Zhou QG, Hou FF, Guo ZJ, Liang M, Wang GB, Zhang X. 1,25-Dihydroxyvitamin D improved the free fatty-acid-induced insulin resistance in cultured C2C12 cells. Diabetes Metab Res Rev. 2008; 24(6):459–64.